Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase NA 2Phase 1 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Cancer 2Small Cell Lung Cancer Limited Stage 1Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Advanced Cervical Cancer 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × anlotinib × Clear all
NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Fudan University

Phase 1 Recruiting
42 enrolled
Breast

Breast Neoplasms

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Peking University Cancer Hospital & Institute

Phase 1 Unknown
52 enrolled
BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡